Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs docetaxel in advanced/metastatic NSCLC after platinum failure (China)
CTR20150767Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Nov 2015; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20150767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150767.